{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:48:36Z","timestamp":1775868516793,"version":"3.50.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The incidence of DLBCL in elderly patients has been gradually increased. Considering their comorbidities and performance status, the first-line standard treatment hasn\u2019t been determined for the elderly.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a systemic review and network meta-analysis to compare the efficacy and safety of all eligible regimens as first line treatment for elderly patients with DLBCL. We searched PubMed, Cochrane Library, and Embase Library proceedings up to March 2022.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our search yielded thirteen trials including 1839 patients. R2CHOP21 showed the best PFS with a statistical difference and the most favorable OS without a statistical difference. RCOMP showed the most clinical benefits in EFS, CR and OR with no significant difference. The point estimate was in favored improved DFS with RCHOP14 than RCHOP21, although this was not statistically significant. In a subgroup analysis concerning 3-4 grade AEs revealed R-COMP was associated with a decrease in grade III\/IV neutropenia and cardiac toxic events; RminiCEOP was associated with the lower rates of 3-4 grade anemia, thrombocytopenia and infection; RCHOP21 had the lowest rate of 3-4 grade AE of neurotoxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The findings of our meta-analysis indicated that R2CHOP21 provided the best disease control in PFS and represented an optimal first-line treatment option in the elderly with DLBCL. Furthermore, RCOMP, RminiCEOP and RCHOP21 exhibited lower rates in different 3-4 grade AEs and might be reasonable treatment options in the elderly with poor general conditions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1082293","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T13:49:44Z","timestamp":1672840184000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of first-line treatments for elderly patients with diffuse large B-cell lymphoma: A systematic review and network meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Yangyang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiyang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keke","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianfang","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linhui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhimin","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the world health organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1365-2141.2011.08934.x","article-title":"Analysis of very elderly (>\/=80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome","volume":"156","author":"Nabhan","year":"2012","journal-title":"Br J Haematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's haematological malignancy research network","volume":"112","author":"Smith","year":"2015","journal-title":"Br J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s41999-019-00265-2","article-title":"Worldwide disease epidemiology in the older persons","volume":"11","author":"Mattiuzzi","year":"2020","journal-title":"Eur Geriatr Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-b-cell lymphoma: 6-year results of an open-label randomised study of the MabThera international trial (MInT) group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the groupe d'Etudes des lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large b-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.810737","article-title":"Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large b-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome","volume":"55","author":"Boslooper","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25582","article-title":"Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large b-cell non-Hodgkin lymphoma","volume":"117","author":"Musolino","year":"2011","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large b-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30171-5","article-title":"Combination of ofatumumab and reduced-dose CHOP for diffuse large b-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group","volume":"4","author":"Peyrade","year":"2017","journal-title":"Lancet Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.621565","article-title":"Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly \"fit\" patients with diffuse large b-cell lymphoma: results from the ANZINTER3 trial of the intergruppo italiano linfomi","volume":"53","author":"Merli","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ b-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.406.406","article-title":"R-CHOP14 compared to r-CHOP21 in elderly patients with diffuse Large b-cell lymphoma: Results of the interim analysis of the LNH03-6B GELA study","volume":"114","author":"Delarue","year":"2009","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.8000","article-title":"R-CHOP14 versus r-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large b-cell non-Hodgkin lymphoma","volume":"29","author":"Cunningham","year":"2011","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3730","article-title":"R-COMP versus r-CHOP as first-line therapy for diffuse large b-cell lymphoma in patients >\/=60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group","volume":"10","author":"Sancho","year":"2021","journal-title":"Cancer Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002982","article-title":"Long-term outcomes of r-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines","volume":"5","author":"Moccia","year":"2021","journal-title":"Blood Adv"},{"key":"B18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"14","author":"Methley","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-hodgkin's lymphomas. NCI sponsored international working group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/ncb2784","article-title":"A complex secretory program orchestrated by the inflammasome controls paracrine senescence","volume":"15","author":"Acosta","year":"2013","journal-title":"Nat Cell Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1101\/gad.343129.120","article-title":"Senescence and the SASP: many therapeutic avenues","volume":"34","author":"Birch","year":"2020","journal-title":"Genes Dev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.661988","article-title":"Identification of aging-related genes associated with clinical and prognostic features of hepatocellular carcinoma","volume":"12","author":"Chen","year":"2021","journal-title":"Front Genet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse Large b-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03418","article-title":"Rituximab-CHOP with early rituximab intensification for diffuse Large b-cell lymphoma: A randomized phase III trial of the HOVON and the Nordic lymphoma group (HOVON-84)","volume":"38","author":"Lugtenburg","year":"2020","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01375","article-title":"Addition of lenalidomide to r-CHOP improves outcomes in newly diagnosed diffuse Large b-cell lymphoma in a randomized phase II US intergroup study ECOG-ACRIN E1412","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-r compared with r-CHOP as frontline therapy for diffuse Large b-cell lymphoma: Clinical outcomes of the phase III intergroup trial Alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70122-0","article-title":"Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large b-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial","volume":"14","author":"Delarue","year":"2013","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt289","article-title":"Comparison of pixantrone-based regimen (CPOP-r) with doxorubicin-based therapy (CHOP-r) for treatment of diffuse large b-cell lymphoma","volume":"24","author":"Herbrecht","year":"2013","journal-title":"Ann Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx128","article-title":"Outcome of elderly patients with diffuse large b-cell lymphoma treated with r-CHOP: results from the UK NCRI r-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial","volume":"28","author":"Kuhnl","year":"2017","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30051-1","article-title":"Anthracycline dose optimisation in patients with diffuse large b-cell lymphoma: a multicentre, phase 3, randomised, controlled trial","volume":"6","author":"Xu","year":"2019","journal-title":"Lancet Haematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2021.1898048","article-title":"R-CHOP compared to r-CHOP + X for newly diagnosed diffuse large b-cell lymphoma: a systematic review and meta-analysis","volume":"60","author":"Pasvolsky","year":"2021","journal-title":"Acta Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70251-0","article-title":"Rituximab in DLBCL: 6 years on","volume":"12","author":"Cabanillas","year":"2011","journal-title":"Lancet Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive b-cell non-hodgkin's lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2818","article-title":"A phase 2\/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator's choice in patients with relapsed or refractory diffuse Large b-cell lymphoma","volume":"23","author":"Czuczman","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2613","article-title":"Frontline treatment of diffuse large b-cell lymphoma: Beyond r-CHOP","volume":"37","author":"Mondello","year":"2019","journal-title":"Hematol Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1444","article-title":"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer","volume":"19","author":"Batist","year":"2001","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/1471-2407-10-337","article-title":"Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials","volume":"10","author":"Smith","year":"2010","journal-title":"BMC Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/hon.827","article-title":"Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines","volume":"25","author":"Rigacci","year":"2007","journal-title":"Hematol Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802043853","article-title":"R-COMP 21 for frail elderly patients with aggressive b-cell non-Hodgkin lymphoma: a pilot study","volume":"49","author":"Visani","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"B41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1053\/j.seminoncol.2004.08.001","article-title":"Advantages of liposomal delivery systems for anthracyclines","volume":"31","author":"Allen","year":"2004","journal-title":"Semin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1082293\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T13:49:48Z","timestamp":1672840188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1082293\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2022.1082293"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1082293","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"article-number":"1082293"}}